Rahul Kumar Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rahul Kumar Singh has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Kumar Das
Department of Chemistry, University of North Bengal, Darjeeling, West Bengal, India
6 shared publications Deboshmita Mukherjee
3 shared publicationsDilip Sarkar
Department of Chemistry, University of North Bengal, Darjeeling, WB, India
3 shared publicationsArpita Das
Department of Biotechnology, University of North Bengal, Darjeeling, WB, India
2 shared publicationsBakibillah
2 shared publicationsSaranita Roy Chowdhury
Department of Chemistry, University of North Bengal, Darjeeling, WB, India
2 shared publications
Latest Publications
- 27 February 2026
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 205, 111597
Integrating experimental and computational approaches to explore the anticancer potential of a pyridine-based reduced Schiff base
- 27 February 2026
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 205, 111597
Integrating experimental and computational approaches to explore the anticancer potential of a pyridine-based reduced Schiff base
- 21 January 2026
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 24 (6) , 1295-1317
Hydrogen borrowing enabled Cp*Ir( iii )-catalyzed C3 alkylation of indoles and oxindoles
An iridium(III) complex bearing a picolinamidato ligand has been developed as an efficient catalyst for the regioselective C3 alkylation of indoles and oxindoles via a borrowing hydrogen (BH) or hydrogen autotransfer strategy. A broad range of aromatic, heteroaromatic, and aliphatic alcohols, including diols, are successfully employed under solvent-free (neat) conditions with low catalyst loading, demonstrating excellent functional group tolerance. Significantly, this protocol combines high regioselectivity, atom economy, and operational simplicity by avoiding preactivated alkylating agents, external oxidants, or reductants, thereby advancing sustainable C–C bond-forming methodologies. The method is scalable and provides straightforward access to structurally diverse and biologically relevant indole and oxindole frameworks, which are prevalent motifs in pharmaceuticals and natural products. Control experiments, deuterium labeling studies, and spectroscopic investigations support a classical borrowing hydrogen mechanism involving Ir–hydride intermediates.
- 21 January 2026
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 24 (6) , 1295-1317
Hydrogen borrowing enabled Cp*Ir( iii )-catalyzed C3 alkylation of indoles and oxindoles
An iridium(III) complex bearing a picolinamidato ligand has been developed as an efficient catalyst for the regioselective C3 alkylation of indoles and oxindoles via a borrowing hydrogen (BH) or hydrogen autotransfer strategy. A broad range of aromatic, heteroaromatic, and aliphatic alcohols, including diols, are successfully employed under solvent-free (neat) conditions with low catalyst loading, demonstrating excellent functional group tolerance. Significantly, this protocol combines high regioselectivity, atom economy, and operational simplicity by avoiding preactivated alkylating agents, external oxidants, or reductants, thereby advancing sustainable C–C bond-forming methodologies. The method is scalable and provides straightforward access to structurally diverse and biologically relevant indole and oxindole frameworks, which are prevalent motifs in pharmaceuticals and natural products. Control experiments, deuterium labeling studies, and spectroscopic investigations support a classical borrowing hydrogen mechanism involving Ir–hydride intermediates.
- 9 November 2025
- Published by Elsevier in Polyhedron
- Vol. 284
Design of an NNO-based fluorogenic chemosensor for Hg2+ ion detection: Structural characterization and biological imaging in cells and zebrafish
- 9 November 2025
- Published by Elsevier in Polyhedron
- Vol. 284
Design of an NNO-based fluorogenic chemosensor for Hg2+ ion detection: Structural characterization and biological imaging in cells and zebrafish
- 1 July 2025
- Published by Elsevier in Tetrahedron
- Vol. 185
Cp∗Ir(III) Catalyzed greener synthesis of nitrogenous heterocycles using acceptor less dehydrogenative coupling (ADC) strategy
- 1 July 2025
- Published by Elsevier in Tetrahedron
- Vol. 185
Cp∗Ir(III) Catalyzed greener synthesis of nitrogenous heterocycles using acceptor less dehydrogenative coupling (ADC) strategy
- 6 March 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (1) , 41
In-silico repurposing of antiviral compounds against Marburg virus: a computational drug discovery approach
The Marburg virus (MARV), a member of the family Filoviridae, is a highly pathogenic virus causing severe hemorrhagic fever with extremely high mortality in humans and non-human primates. The MARV exhibits clinical and epidemiological features almost identical to those of the Ebola virus, no licensed vaccines or antiviral treatments have been developed yet for MARV. However, only a few treatments that remain uncertain of the disease are available to help bring a case for a new therapeutic approach. Considering the non-availability of any standard drug we have planned to identify potential inhibitors of VP24 (PDB ID: 4OR8) through a computational drug repurposing process. The workflow includes: identifying a druggable pocket on VP24, screening of FDA-approved antivirals via molecular docking, assessing the stability using molecular dynamics simulations, and estimating binding affinity through MM-PBSA calculations. After going through the analysis, the compound Bictegravir manifests as a hit compound which will undergo in vitro and in vivo validation to confirm its efficacy against MARV. The online version contains supplementary material available at 10.1007/s40203-025-00323-7.
- 6 March 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (1) , 41
In-silico repurposing of antiviral compounds against Marburg virus: a computational drug discovery approach
The Marburg virus (MARV), a member of the family Filoviridae, is a highly pathogenic virus causing severe hemorrhagic fever with extremely high mortality in humans and non-human primates. The MARV exhibits clinical and epidemiological features almost identical to those of the Ebola virus, no licensed vaccines or antiviral treatments have been developed yet for MARV. However, only a few treatments that remain uncertain of the disease are available to help bring a case for a new therapeutic approach. Considering the non-availability of any standard drug we have planned to identify potential inhibitors of VP24 (PDB ID: 4OR8) through a computational drug repurposing process. The workflow includes: identifying a druggable pocket on VP24, screening of FDA-approved antivirals via molecular docking, assessing the stability using molecular dynamics simulations, and estimating binding affinity through MM-PBSA calculations. After going through the analysis, the compound Bictegravir manifests as a hit compound which will undergo in vitro and in vivo validation to confirm its efficacy against MARV. The online version contains supplementary material available at 10.1007/s40203-025-00323-7.
- 5 February 2025
- Published by Springer Nature in Chemistry Africa
- Vol. 8 (3) , 1015-1032
Synthesis, Characterization, Antimicrobial and Biomimetic Catalytic Activity of Dicyanamide Based Cu(II) Complex
- 5 February 2025
- Published by Springer Nature in Chemistry Africa
- Vol. 8 (3) , 1015-1032
Synthesis, Characterization, Antimicrobial and Biomimetic Catalytic Activity of Dicyanamide Based Cu(II) Complex